Franco Granella

List of Publications by Year
in descending order

81	4,073	136950	123424
papers	citations	32 h-index	61 g-index

83	83	83	3660
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	5.3	370
2	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336
3	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	7.6	281
4	Migraine Without Aura and Reproductive Life Events: A Clinical Epidemiological Study in 1300 Women. Headache, 1993, 33, 385-389.	3.9	257
5	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	10.2	219
6	Multicenter Case-Control Study on Restless Legs Syndrome in Multiple Sclerosis: the REMS Study. Sleep, 2008, 31, 944-952.	1.1	175
7	Predictors of longâ€term disability accrual in relapseâ€onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	5.3	158
8	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134
9	Italian guidelines for primary headaches: 2012 revised version. Journal of Headache and Pain, 2012, 13, 31-70.	6.0	129
10	Nocturnal Eating Syndrome in Adults. Sleep, 1994, 17, 339-344.	1.1	108
11	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	9.0	100
12	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	7.6	94
13	Course of primary headaches during hormone replacement therapy. Maturitas, 2001, 38, 157-163.	2.4	93
14	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86
15	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	7.6	76
16	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	1.9	71
17	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	1.9	63
18	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.1	54

#	Article	IF	Citations
19	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	7.6	53
20	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	3.0	52
21	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	1.9	49
22	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	3.5	48
23	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860.	3.6	43
24	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.1	41
25	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.1	38
26	Treatment of multiple sclerosis with rituximab: A multicentric Italianâ€“Swiss experience. Multiple Sclerosis Journal, 2020, 26, 1519-1531.	3.0	38
27	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain, 2022, 145, 2796-2805.	7.6	38
28	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	3.0	37
29	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040.	3.0	37
30	Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium. Journal of Headache and Pain, 2008, 9, 367-373.	6.0	35
31	Definitive childlessness in women with multiple sclerosis: a multicenter study. Neurological Sciences, 2017, 38, 1453-1459.	1.9	35
32	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	2.0	35
33	A New 5-HT2 Antagonist (Ritanserin) in the Treatment of Chronic Headache With Depression. A Double-Blind Study vs Amitriptyline. Headache, 1990, 30, 439-444.	3.9	34
34	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	1.6	33
35	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	7.6	32
36	Risk of Getting COVID-19 in People With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	31

#	Article	IF	Citations
37	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	3.0	30
38	Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. Journal of Neurology, 2013, 260, 1583-1593.	3.6	29
39	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.0	29
40	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1297-1303.	1.9	27
41	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	9.0	26
42	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24
43	Correlation between cortical lesions and cognitive impairment in multiple sclerosis. Brain and Behavior, 2018, 8, e00955.	2.2	23
44	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2019, 36, 101430.	2.0	23
45	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders, 2018, 19, 105-108.	2.0	22
46	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. Frontiers in Neurology, 2019, 10, 916.	2.4	21
47	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Computer Methods and Programs in Biomedicine, 2021, 208, 106180.	4.7	21
48	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurology, 2018, 75, 1407.	9.0	20
49	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology, 2020, 267, 3008-3020.	3.6	19
50	Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease. Multiple Sclerosis and Related Disorders, 2019, 32, 27-29.	2.0	18
51	Previous treatment influences fingolimod efficacy in relapsingâ€“remitting multiple sclerosis: results from an observational study. Current Medical Research and Opinion, 2014, 30, 1849-1855.	1.9	17
52	Spinal cord lesions are frequently asymptomatic in relapsingâ€“remitting multiple sclerosis: a retrospective MRI survey. Journal of Neurology, 2019, 266, 3031-3037.	3.6	17
53	First-line disease-modifying drugs in relapsingâ€“remitting multiple sclerosis: an Italian real-life multicenter study on persistence. Current Medical Research and Opinion, 2018, 34, 1803-1807.	1.9	13
54	The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study. Multiple Sclerosis and Related Disorders, 2019, 33, 146-152.	2.0	13

#	Article	IF	Citations
55	Migraine Awareness in Italy and the Myth of â€œCervical Arthrosisâ€. Headache, 2020, 60, 81-89.	3.9	13
56	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	3.0	13
57	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. Neurology, 2022, 98, .	1.1	12
58	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	3.0	11
59	Health-related quality of life in clinically isolated syndrome and risk of conversion to multiple sclerosis. Neurological Sciences, 2019, 40, 75-80.	1.9	10
60	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. Journal of Neurology, 2022, 269, 933-944.	3.6	10
61	Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month) Tj ETQq1 1 0.784314 rgBT /Overlo 414, 116827.	0.6	9
62	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Journal of the Neurological Sciences, 2021, 430, 118067.	0.6	9
63	Silent lesions on MRI imaging â€“ Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	3.0	8
64	The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
65	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	5.9	8
66	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.3	8
67	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	3.0	7
68	Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	3.3	6
69	Comparing natural history of early and late onset pediatric multiple sclerosis. Annals of Neurology, 2022, , .	5.3	6
70	Hemicrania horologica (â€œclock-like hemicraniaâ€). Neurology, 2003, 60, 1722-1723.	1.1	4
71	Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. Neuroepidemiology, 2021, 55, 224-231.	2.3	4
72	Neuromyelitis Optica Spectrum Disorder Attack Triggered by Herpes Zoster Infection. Multiple Sclerosis International, 2020, 2020, 1-3.	0.8	3

#	Article	IF	Citations
73	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	3.0	3
74	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	3.3	3
75	Inhaled migraine drug therapy: a start of the art therapeutic strategy or just another gimmick?. Expert Opinion on Pharmacotherapy, 2018, 19, 1743-1745.	1.8	2
76	Location of first attack predicts the site of subsequent relapses in multiple sclerosis. Journal of Clinical Neuroscience, 2020, 74, 175-179.	1.5	2
77	Secondary cluster headache due to a contralateral demyelinating periaqueductal gray matter lesion. Headache, 2021, 61, 1136-1139.	3.9	2
78	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	3.0	2
79	Herpes zoster preceding neuromyelitis optica spectrum disorder: casual or causal relationship? A systematic literature review. Journal of NeuroVirology, 2022, 28, 201-207.	2.1	2
80	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
81	Reply to: Comment on Y.D. Fragoso et al.: â€œLymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodâ€•[Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	2.0	0